$0.190
-0.076 (-39.99%)Zum Schluss
SSKN-News
SSKN-Events
Strata Skin Sciences Appoints Erica Jordan as CEO
Strata Skin Sciences appointed industry veteran Erica Jordan as CEO, effective July 12. Prior to joining Strata, Jordan served as chief commercial officer for Revance Therapeutics.
Strata Skin Sciences Files Form 25 to Deregister Stock
Strata Skin Sciences announces that a Form 25 has been filed today with the SEC to deregister its common stock under Section 12(b) of the Securities Exchange Act of 1934, as amended, and confirms that trading of the company's common stock has been suspended from trading on The Nasdaq Capital Market at the opening of business on February 19. "The pathway taken by the Company was not due to any financial instability of the Company or any weakening in the Company's business," said Dolev Rafaeli, CEO and vice chairman. "In fact, the Company finished the 2025 fiscal year with a very strong balance sheet, which included $8 million in cash."
STRATA Skin Sciences Partners with Johns Hopkins Dermatology to Introduce XTRAC Laser
STRATA Skin Sciences announces that Johns Hopkins Dermatology has added the XTRAC 308 nm excimer laser to its clinical treatment offerings. The addition of XTRAC enhances Johns Hopkins' ability to deliver advanced, targeted care for patients living with chronic inflammatory and autoimmune skin diseases, including psoriasis, vitiligo, atopic dermatitis, and other complex dermatologic conditions. The technology will also support ongoing clinical research and academic initiatives within the department, reinforcing its commitment to evidence-based dermatologic innovation.
Strata Skin Sciences Confirms Clinical Efficacy of 308nm Excimer Laser for Psoriasis
Strata Skin Sciences highlights findings from a February 2026 systematic review and meta-analysis confirming the clinical efficacy of 308 nm Excimer laser in plaque psoriasis. Published in the Journal of Drugs in Dermatology by investigators from Georgetown University School of Medicine and the Department of Dermatology at MedStar Washington Hospital Center, the analysis evaluated clinical trials assessing the efficacy of the 308 nm excimer laser for plaque psoriasis. "This meta-analysis reinforces what dermatologists have observed clinically - that properly calibrated, MED-guided Excimer Laser therapy provides effective, targeted treatment for plaque psoriasis," said Dr. Dolev Rafaeli, STRATA Skin Sciences Chief Executive Officer. "Enabling the delivery of high-fluence 308nm UVB precisely to affected plaques while sparing surrounding healthy skin represents a meaningful therapeutic advantage."
Strata Skin Sciences Receives COFEPRIS Approval for TheraClear in Mexico
STRATA Skin Sciences announced that its TheraClearX acne treatment system has received regulatory clearance from the Mexican health authority, COFEPRIS, under Device Registration No. 3187E2024SSA, valid through November 2029. This certification represents a major milestone in STRATA's international expansion strategy, officially authorizing the importation, commercialization, and clinical use of TheraClearX(R) across Mexico's medical and aesthetic markets.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.